Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome.
- Author:
Ya-Qin ZHI
1
;
Shan-Qi GUO
;
Yi-Zhuo ZHANG
Author Information
1. Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
- Publication Type:Journal Article
- MeSH:
Epigenesis, Genetic;
Histone Deacetylase Inhibitors;
therapeutic use;
Humans;
Myelodysplastic Syndromes;
drug therapy;
genetics
- From:
Journal of Experimental Hematology
2012;20(3):792-795
- CountryChina
- Language:Chinese
-
Abstract:
The effects of conventional treatment for myelodysplastic syndrome (MDS) are not remarkable to date, while only a minority of patients was eligible for allogeneic stem cell transplantation. As epigenetics plays a significant role during the occurrence and development of MDS, and histone deacetylase inhibitors (HDACI), a class of gene expression modulating drugs, are currently being developed for therapy of several types of solid tumor, more attention is paying to HDACI as potential therapy of MDS. This review summarizes briefly the rationale for HDACI use in MDS, the common mechanism of HDACI, the present state of the clinical efficiency, and future development in this field.
